Brilaroxazine

N/A

Report date: 2024/06/17 16:39:15
NME

Base Information

Drug NameBrilaroxazine
Drug Alias Namebrilaroxazine lipogelRP-5000RP-5063
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1a (5-HT1a) receptor partial agonistsDopamine D4 receptor partial agonistsDopamine D3 receptor partial agonists +[7] 
TargetsSerotonin 1a (5-HT1a) receptorDopamine D4 receptorDopamine D3 receptor +[7] 
Therapy Area/IndicationsSchizophreniaAttention Deficit Disorder with HyperactivityDepressive Disorder, Major +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPhilippinesIndia +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesReviva Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesReviva Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSchizophreniaAttention Deficit Disorder with HyperactivityDepressive Disorder, Major +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank